Clinical Trial Update: Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update for Xeligekimab in treating moderate to severe Palmoplantar Pustulosis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmoplantar Pustulosis

Drugs mentioned

• Xeligekimab

Snippet

Sponsor: First Hospital of China Medical University | Conditions: Palmoplantar Pustulosis (PPP) | Phase 4 | Status: RECRUITING